

"Express Mail" mailing label number EL 856 148 653 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on December 18, 2001

By

Printed: Junior Martinez



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Coleman et al.

Title: NOVEL HUMAN C5A-LIKE RECEPTOR

Serial No.: To Be Assigned

Filing Date: Herewith

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

---

Commissioner for Patents  
Box Patent Application  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Applicants respectfully submit under 37 C.F.R. 1.98(3)(d) that copies of the references are not included herein as copies were previously cited by or submitted to the Office in parent application Serial No. 08/791,974, filed January 31, 1997, from which we are claiming priority under 35 U.S.C. 120.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have

an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**.

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: December 18, 2001

Barrie D. Greene

Barrie D. Greene

Reg No. 46,740

Direct Dial Telephone: (650) 621-7576

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office	Atty Docket No.	Serial No.
	PF-0198-1 CON	To Be Assigned
LIST OF REFERENCES CITED BY APPLICANTS	Applicant	
(Use several sheets if necessary)	Coleman et al.	
	Filing Date	Group
	To Be Assigned	To Be Assigned

## U.S. Patent Documents

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	1	5,723,315	03/03/98	Jacobs et al.	435	69.1	
	2	5,525,495	09/15/93	Keene et al.	435	172.3	

## Foreign Patent Documents

							Translation	
		Document	Date	Country	Class	Subclass	Yes	No
	3	WO 98/07859	26 Feb 1998	PCT				
	4	EP 0 837 128 A2	22 March 1998	European Patent Office				

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

5	Gerard, N., et al., "The chemotactic receptor for human C5a anaphylatoxin," <u>Nature</u> , 342:614-617 (1991)
6	Boulay, F., et al., "Expression Cloning of a Receptor for C5a Anaphylatoxin on Differentiated HL-60 Cells," <u>Biochem.</u> , 30:2993-2999 (1991)
7	Gerard, C., et al., "C5A ANAPHYLATXIN AND ITS SEVEN TRANSMEMBRANE-SEGMENT RECEPTOR," <u>Annu. Rev. Immunol.</u> , 12:775-808 (1994)
8	Wang, Y., et al., "Amelioration of lupus-like autoimmune disease in NZB/WF <sub>1</sub> mice after treatment with a blocking monoclonal antibody specific for complement component C5," <u>Proc. Natl. Acad. Sci. U.S.A.</u> , 93:8563-8568 (1996)
9	Gasque, P., et al., "Identification and Characterization of the Complement C5a Anaphylatoxin Receptor on Human Astrocytes," <u>J. Immunol.</u> , 155:4882-4889 (1995)
10	Benbow, R., et al., "ROLE OF COMPLEMENT IN ENDOTOXIN/PLATELET ACTIVATING FACTOR-INDUCED LONG INFLUENZA," <u>J. Immunol.</u> , 149:1144-1149 (1992)
11	Belmont, H., et al., "UP-REGULATION OF ENDOTHELIAL CELL ADHESION MOLECULES CHARACTERIZES DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS. The Schwartzman Phenomenon Revisited," <u>Arthritis Rheum.</u> , 37:376-383 (1994)

Examiner

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]